One of the important features of the biological behavior of prostate cancer is its dependence or partial dependence on androgens as “nutrition” for its growth. Because many prostate cancer patients are diagnosed at an advanced stage, hormone therapy is now the accepted first choice for these patients. For this group of patients, clinical treatment measures are currently very limited, and chemotherapy is one of the options. There are a variety of chemotherapy drugs that can be used to treat hormone-non-dependent prostate cancer, including estradiol nitrogen mustard, mitoxantrone, paclitaxel, and vincristine. Estradiol nitrogen mustard is an oral chemotherapeutic agent that has both endocrine therapeutic and cytotoxic effects. It can be considered for some patients who are in poor health and have difficulty receiving intravenous chemotherapy. Among the many intravenous chemotherapy drugs for prostate cancer, docetaxel is the one that has been studied more in recent years. Currently, docetaxel-based chemotherapy regimens are becoming the standard chemotherapy regimen for hormone-independent prostate cancer. There are some adverse effects associated with the use of these chemotherapy regimens for prostate cancer, the most serious of which is a decrease in neutrophils due to chemotherapy. Other adverse effects of chemotherapy are mild, including nausea, fatigue, and diarrhea, and most patients can tolerate them. Of course, there are far more chemotherapy regimens for prostate cancer than the above, and different chemotherapy regimens have their own adverse effects. Therefore, during the process of chemotherapy, you should ask your physician for more advice on what reactions you will experience during the treatment, etc. This mental preparation will help build up your confidence in the treatment.